Close
Patheon

News Releases

  • 15 Mar 2016

    Survey about product launch challenges finds instances of demand forecasts off by more than 50 percent, leading to sales losses and reputation damage

    DURHAM, N.C.--(BUSINESS WIRE)--A survey of 50 pharmaceutical industry senior managers found a majority of companies had either overestimated or underestimated demand for new drugs by up to 25 percent, with some reporting instances of forecasts being off by more than 50 percent. The results of the survey – conducted by business intelligence firm ORC International and sponsored by Patheon, a leading global provider of high-quality drug development and delivery solutions to themore...
  • 14 Mar 2016
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services, announced today that it has signed a manufacturing agreement with Amgen, one of the world’s leading biotechnology companies, headquartered in Thousand Oaks, CA. Amgen has selected Patheon to provide flexible manufacturing solutions to meet the growing demand for their innovative human therapeutics. “As we launch new products and expand intomore...
  • 22 Feb 2016
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®. Patheon was selected tomore...